Bardstown Bourbon Company and Brindiamo Expand Relationship with First-of-its-kind Barrel Leasing Program
9.12.2024 20:21:00 CET | Business Wire | Press release
Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, today announced an exclusive relationship to provide a market-leading barrel leasing program for whiskey brand contract distillation customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209024956/en/

Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, will launch an exclusive barrel leasing program -- a timely, tailored solution for non-distilling brands. Roughly one-third of the cost of a new fill barrel is tied up in the wood used to make the barrel. This program allows brands to simplify this significant upfront expense into manageable monthly payments, offering customers the flexibility to plan for tomorrow while maintaining the cashflow to support their needs today. (Photo: Business Wire)
As the whiskey market continues to evolve, this financing program offers a timely, tailored solution for non-distilling brands. Roughly one-third of the cost of a new fill barrel is tied up in the wood used to make the barrel. This program allows brands to simplify this significant upfront expense into manageable monthly payments, offering customers the flexibility to plan for tomorrow while maintaining the cashflow to support their needs today.
“At Bardstown, we pride ourselves on quality, consistency, customer service and innovation. This program was designed to provide an alternative financing solution to customers looking to acquire the highest quality and most consistent distillate available,” said Mark Erwin, Bardstown Bourbon Company CEO. “We are expanding our relationship with long-term partner Brindiamo to exclusively represent this program to our customers.”
While the program will initially be limited to 25,000 barrels annually, Bardstown and Brindiamo are committed to growing the program to meet customer demand. Both sales teams will market and sell the program with Brindiamo serving as the exclusive manager for this innovative offering.
“Bardstown and Green River have been great partners of ours for years, and we admire their ‘Never Stand Still’ attitude. This program is a natural evolution of our collaboration,” said Jeff Steinberg, CEO of Brindiamo. “In today’s economic climate, we believe that customers will prefer the flexibility of leasing the wood to free up capital for their sales and marketing efforts. We are excited to develop this offering with Bardstown Bourbon.”
“Brindiamo is the perfect partner for this as they have the scale, know-how and capability to build a superlative end-to-end experience for our customers,” said Erwin. “We take great pride in creating unprecedented value for our customers and this innovation directly responds to their needs in the face of the market dynamics impacting many brands.”
For questions or to learn more about the barrel leasing program visit bardstownbourbon.com/contract-distilling.
High res imagery and assets can be found here.
About Bardstown Bourbon Company
Bardstown Bourbon Company is pushing the boundaries of innovation while honoring the traditional art of making great whiskey. With the most modern, technically advanced whiskey distillery, Bardstown Bourbon Co. combines distillation and spirited hospitality into a modern, authentic bourbon experience unlike any other on the Kentucky Bourbon Trail™. Named 2023 Worldwide Whiskey Producer of the Year by IWSC and boasting the highest rated bourbon in the world, Bardstown Bourbon Co. is working to push the entire industry in a direction that is more innovative, more transparent and more collaborative. Bardstown Bourbon Co is a top ten distiller by volume in the U.S. For more information visit BardstownBourbon.com.
About Brindiamo
Brindiamo is a leading partner to the global whiskey industry, offering expertise and tailored solutions to brands, distilleries, and suppliers. Known for its ability to simplify complexity, Brindiamo specializes in barrel and liquid management, financing, logistics, and strategic services that help clients navigate the challenges of whiskey production. As the premier sourcing partner for bulk American, Scotch, Irish, and world whiskies, Brindiamo provides unparalleled access to premium liquid. Brindiamo supports its partners every step of the way, delivering creative solutions and unmatched value from wood to glass.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209024956/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom